论文部分内容阅读
目的:评价玻璃体内地塞米松缓释植入物(傲迪适，Ozurdex)治疗视网膜静脉阻塞继发黄斑水肿的临床效果。方法:回顾性系列病例研究。分析郑州大学第一附属医院2018年12月至2019年9月视网膜静脉阻塞继发黄斑水肿应用玻璃体内植入傲迪适治疗的17例(18只眼)的临床资料。术后随访6个月以上。观察植入前后视力、视网膜中心区厚度及并发症。结果:植入前视力(BCVA，logMAR)为0.93±0.70，植入后1、2、3、4、5、6个月依次为0.55±0.49、0.47±0.48、0.48±0.48、0.53±0.65、0.46±0.53、0.41±0.51，植入前与植入后不同时间点视力的差异有统计学意义(n F＝41.720，n P＝0.000)，植入后各时间点视力的差异均无统计学意义(n P>0.05)；植入前视网膜中心区厚度为(640.72±181.80)μm，植入后1、2、3、4、5、6个月依次为(318.39±143.54)μm、(234.44±85.71)μm、(367.00±178.61)μm、(321.83±137.67)μm、(288.94±121.55)μm、(271.72±111.96)μm，均较植入前明显降低(n F＝6.347，n P＝0.000)；植入后3个月视网膜中心区厚度较植入后2个月有所增加，差异有统计学意义(n P＝0.032)，余各随访时间点差异无统计学意义(n P>0.05)。随访期间有11只眼黄斑水肿复发，平均复发时间(3.27±0.65)个月，未发生眼部或全身严重并发症。n 结论:地塞米松玻璃体内植入物植入治疗视网膜静脉阻塞引起的黄斑水肿，可有效减轻水肿并提高视力。“,”Objective:To evaluate the clinical efficacy of dexamethasone intravitreal implant (Ozurdex) for the treatment of macular edema secondary to retinal vein occlusion.Methods:This was a retrospective series case study. The clinical data of 18 eyes of 17 cases treated with intravitreal implant of Ozurdex for macular edema secondary to retinal vein occlusion from Dec. 2018 to Sep. 2019 in the First Affiliated Hospital of Zhengzhou University were analyzed. All patients were followed-up for more than 6 months. The visual acuity, the thickness of the central retina and complications before and after implantation were observed.Results:The visual acuity (BCVA, logMAR) before implantation was 0.93±0.70, and at 1, 2, 3, 4, 5, 6 months after implantation were 0.55±0.49, 0.47±0.48, 0.48±0.48, 0.53±0.65, 0.46±0.53, 0.41±0.51. The difference of visual acuity before and after implantation was statistically significant (n F=41.720, n P=0.000). The thickness of the central retina before implantation was (640.72±181.80) μm, and at 1, 2, 3, 4, 5, 6 months after implantation were (318.39±143.54) μm, (234.44±85.71) μm, (367.00±178.61) μm, (321.83±137.67) μm, (288.94±121.55) μm, (271.72±111.96) μm. The difference was statistically significant between before and after implantation ( n F=6.347, n P=0.000). The thickness of central retina at 3 months after implantation was higher than that at 2 months after implantation. The difference was statistically significant (n P=0.032). There was no significant difference in other followed-up time points (n P>0.05). Macular edema recurred in 11 eyes during the follow-up period, and the average recurrence time was (3.27±0.65) months. No serious ocular or systemic complication occurred.n Conclusion:Intravitreal implantation of dexamethasone implant can effectively reduce macular edema and improve vision for the treatment of macular edema caused by retinal vein occlusion.